First AD

Second AD

Briefly comment on the addition of doublet venetoclax-ibrutinib as a treatment option in ESMO guideline updates and highlight the underlying rationale and data supporting this approach.

Doublet Therapy With Venetoclax-Ibrutinib: Data and Guidelines

Video content above is prompted by the following:

Video Series

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Chronic Lymphocytic Leukemia

 Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy. 

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


ASH 2024: Global Updates in the Management of Chronic Lymphocytic Leukemia  

Peer Exchange

Panelists discuss the addition of doublet venetoclax-ibrutinib as a treatment option in ESMO guideline updates.